Navigation Links
ViroPharma Announces Initiation Of Non-Toxigenic Clostridium Difficile Phase 1 Program
Date:8/6/2009

d Dale N. Gerding, MD, Associate Chief of Staff for Research at the Hines VA Hospital. "Despite the effectiveness of current acute treatment options, CDI recurrence remains a significant unmet medical need and NTCD presents a unique opportunity to not only reduce CDI recurrent disease but to also potentially prevent primary CDI in high-risk patients taking antibiotics."

About Clostridium difficile

One of the most serious problems facing the U.S. healthcare system today is hospital-acquired infections (HAIs) and Clostridium difficile infection is one of the most common and devastating HAIs. The incidence of Clostridium difficile observed in U.S. healthcare facilities more than doubled approximately every five years since 1999 and the reported mortality rates from Clostridium difficile in the U.S. have more than quadrupled in the last decade to 23.7 per million. Elderly patients exposed to antibiotics, long-term care patients, or those who have a serious underlying illness are at greatest risk to contract the disease. Patients with this disease have GI tract conditions that are significantly different from those of a healthy individual due to infection. Typical symptoms include diarrhea (which can be severe), fever, nausea, abdominal pain, and dehydration, though cases can lead to life-threatening complications such as megacolon, peritonitis and perforation of the colon.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-r
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. ViroPharma to Present at the Maxim Group First Annual Growth Conference
2. ViroPharma to Present at the UBS Global Life Sciences Conference
3. ViroPharma Incorporated Reports Third Quarter and Nine-Month 2007 Financial Results
4. ViroPharma Receives European Orphan Drug Designation for CAMVIA(TM)
5. ViroPharma to Present at the 26th Annual JP Morgan Healthcare Conference
6. ViroPharma Augments Senior Management
7. ViroPharma Provides Update on Vancocin(R)
8. Vincent J. Milano to Succeed Michel de Rosen as President and Chief Executive Officer of ViroPharma
9. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2007 Financial Results
10. ViroPharma Incorporated Reports First Quarter 2008 Financial Results
11. ViroPharma to Release 2008 Second Quarter Financial Results on July 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... (PRWEB) October 31, 2014 Springboard ... for its small scale BioPro™ biodiesel processors, announced ... will further improve the performance and efficiency of ... GL95/MC12/BD380 trio will recover more than ... in with the glycerin by-product produced while making ...
(Date:10/31/2014)... (PRWEB) October 31, 2014 The Memory Healer ... created by Alexander Lynch, whose father suffered from Alzheimer's disease. ... dramatic moment, caused by his father's disease. His father pointed ... was the crucial moment when the author of this method ... dad. , The Memory Healer program is based on ...
(Date:10/31/2014)... Missouri (PRWEB) October 31, 2014 At ... country about families narrowly escaping carbon monoxide poisoning in ... looms just weeks away, one family-owned, Missouri-based heating and ... approach to making sure families start the home heating ... safe and secure. , Beginning Nov. 1, 2014, ...
(Date:10/31/2014)... 2014 (HealthDay News) -- Surgery for low back pain ... the United States you live, a new report says. ... back pain at some point in their lives, and ... care for a spine problem," co-author Brook Martin, of ... said in a college news release. In spinal ...
(Date:10/31/2014)... – New research suggests that insomnia is a major ... other unintentional fatal injuries. The results underscore the importance ... National Healthy Sleep Awareness Project. , Results show that ... dose-dependent manner with the number of insomnia symptoms present. ... times more likely to die from a fatal injury ...
Breaking Medicine News(10 mins):Health News:Springboard Biodiesel Announces Release of New and Unique Methanol Recovery and Glycerin Treatment Equipment 2Health News:Springboard Biodiesel Announces Release of New and Unique Methanol Recovery and Glycerin Treatment Equipment 3Health News:"Memory Healer" Review Reveals a New Natural Remedy Guide for Managing Memory Loss 2Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 2Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 3Health News:Spinal Surgery Varies by Region in U.S.: Study 2Health News:Insomnia increases risk of motor vehicle deaths, other fatal injuries 2
... March 17 eCardio Diagnostics ( www.ecardio.com ) ... Academic Medicine initiative to provide a tailored offering ... first time an arrhythmia monitoring company has addressed ... academic medical centers. "At eCardio, we work ...
... Pa., March 16 BioTrends Research Group, Inc. has ... through its TreatmentTrends(TM) series which ... survey data collected from Dermatologists and Rheumatologists. The ... of ChartTrends(TM) reports which aim ...
... NATIONALLY BROADCAST ,LIFE PERSPECTIVES, RADIO PROGRAMFRIENDSWOOD, Texas, March 16 ... a developer, manager and owner of faith-based senior living ... a new ticker symbol and will begin trading on ... 17, 2009. The Company also announced that its Chairman ...
... /PRNewswire-Asia-FirstCall/ -- BMP,Sunstone Corporation (Nasdaq: BJGP ) ... Company is calling its $12.4 million of 10.0% Secured,Promissory ... In addition, the,Company announced the completion of the following ... million in principal amount 10.0% senior secured, ...
... Message Spread on Web Sites, YouTubeDon,t Move From ... Human Services to Danger in Rescinding Conscience ProtectionsWASHINGTON, ... Catholics in the United States to tell the ... regulations governing conscience protections for health care workers.This ...
... for Operating Activities Declines to Less Than $1 ... Additional Cost Savings During 2009 & 2010First Quarter ... STAAR Surgical Company (Nasdaq: STAA ... minimally invasive ophthalmic products, today reported financial results ...
Cached Medicine News:Health News:eCardio Diagnostics Launches Academic Medicine Initiative 2Health News:BioTrends Prepares to Field ChartTrends(TM) Reports to Cover the Use of Biologic Agents in Psoriasis and Rheumatoid Arthritis 2Health News:TrinityCare Senior Living Trading Under New Symbol 'TCSR' 2Health News:BMP Sunstone Exchanges and Calls Outstanding Notes Due May 2009 2Health News:Cardinal George Urges Catholics to Tell Administration: Keep Conscience Protections for Health Care Workers 2Health News:Cardinal George Urges Catholics to Tell Administration: Keep Conscience Protections for Health Care Workers 3Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 2Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 3Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 4Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 5Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 6Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 7Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 8Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 9Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 10Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 11Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 12Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 13Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 14Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 15Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 16Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 17Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 18Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 19Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 20Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 21Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 22Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 23Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 24Health News:STAAR Surgical Reports 14% Fourth Quarter Revenue Growth 25
(Date:10/31/2014)... , October 31, 2014 Multigate ... Australian patents of B. Braun Melsungen AG (B. Braun) by ... safety IV catheters manufactured by Poly Medicure Ltd (Polymed). ... Australia proceeding number VID 463 of 2013 can ... the detailed judgment, Multigate was found to have infringed claim ...
(Date:10/31/2014)... Electronic prescribing or E-Prescribing system ... related information between prescriber, dispenser and pharmacy ... and nurse practitioner to transmit a new ... during pharmacy operations. E-Prescribing system has a ... medical lists, conducts all security checks and ...
(Date:10/30/2014)... Oct. 30, 2014 /CNW/ - Atlantic Canadians will save ... between Canada,s provinces and territories ... President of the Canadian Generic Pharmaceutical Association (CGPA), said ... while speaking at the Atlantic Summit on Healthcare and ... which is being hosted by the Public Policy Forum ...
Breaking Medicine Technology:B. Braun Wins Patent Disputes Against Poly Medicure Ltd's Australian Distributor Multigate Medical Devices Pty. Ltd. and Spanish Distributor Dextromédica S. L. 2E-Prescribing Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 2Atlantic Canadians to Save $560-Million Through Unprecedented Three-Year Pan-Canadian Agreement on Generic Prescription Medicines 2Atlantic Canadians to Save $560-Million Through Unprecedented Three-Year Pan-Canadian Agreement on Generic Prescription Medicines 3
... WELLESLEY HILLS, Mass., Feb. 19 Joseph F. ... Creditors of ActivBiotics, announced,today the design of a ... adequately by currently approved antibiotics. Rifalazil, the,most potent ... may,provide a better treatment option for Chlamydia STD. ...
... Show Cethromycin Not Associated with QT Prolongation- ... Cardiac Safety Profile Strengthens NDA-, CHICAGO, Feb. 19 ... today announced positive results from Trial,CL07-001, a thorough QT ... study was conducted to evaluate the cardiac,safety of cethromycin ...
Cached Medicine Technology:ActivBiotics Outlines a Clinical Path Forward to Examine if Rifalazil Is Superior to Azithromycin in the Treatment of Chlamydia STD 2Advanced Life Sciences Announces Successful Thorough QT Study of Cethromycin 2Advanced Life Sciences Announces Successful Thorough QT Study of Cethromycin 3Advanced Life Sciences Announces Successful Thorough QT Study of Cethromycin 4Advanced Life Sciences Announces Successful Thorough QT Study of Cethromycin 5Advanced Life Sciences Announces Successful Thorough QT Study of Cethromycin 6
Tendril DX active-fixation leads allows for lower thresholds initially and during the lead maturation phase....
Tendril DX active-fixation leads allows for lower thresholds initially and during the lead maturation phase....
... Guidant Flextend lead is ... lead with an extendable/retractable ... helix design offers various ... permanent implantation in the ...
The CapSureFix line of pacing leads combines the benefits of steroid-eluting technology with screw-in active fixation, to allow long-lasting, low-threshold delivery of pacing therapies....
Medicine Products: